These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 26765576

  • 1. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
    Merovci A, Abdul-Ghani M, Mari A, Solis-Herrera C, Xiong J, Daniele G, Tripathy D, DeFronzo RA.
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1249-56. PubMed ID: 26765576
    [Abstract] [Full Text] [Related]

  • 2. Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
    Merovci A, Mari A, Solis-Herrera C, Xiong J, Daniele G, Chavez-Velazquez A, Tripathy D, Urban McCarthy S, Abdul-Ghani M, DeFronzo RA.
    J Clin Endocrinol Metab; 2015 May; 100(5):1927-32. PubMed ID: 25710563
    [Abstract] [Full Text] [Related]

  • 3. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
    Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
    [Abstract] [Full Text] [Related]

  • 4. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
    Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E.
    Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1775-81. PubMed ID: 17299078
    [Abstract] [Full Text] [Related]

  • 5. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
    Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Duchesne D, Iqbal N, List J.
    Diabetes Technol Ther; 2014 Mar; 16(3):137-44. PubMed ID: 24237386
    [Abstract] [Full Text] [Related]

  • 6. Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals.
    Daniele G, Eldor R, Merovci A, Clarke GD, Xiong J, Tripathy D, Taranova A, Abdul-Ghani M, DeFronzo RA.
    Diabetes; 2014 Aug; 63(8):2812-20. PubMed ID: 24353180
    [Abstract] [Full Text] [Related]

  • 7. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA.
    Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
    [Abstract] [Full Text] [Related]

  • 8. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
    Ahn CH, Oh TJ, Kwak SH, Cho YM.
    Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
    [Abstract] [Full Text] [Related]

  • 9. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
    Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F, Gambardella A, Giugliano D, D'Onofrio F, Howard BV.
    Diabetologia; 1998 Oct; 41(10):1127-32. PubMed ID: 9794097
    [Abstract] [Full Text] [Related]

  • 10. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
    Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL.
    Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
    [Abstract] [Full Text] [Related]

  • 11. Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects.
    Liang H, Tantiwong P, Sriwijitkamol A, Shanmugasundaram K, Mohan S, Espinoza S, Defronzo RA, Dubé JJ, Musi N.
    J Physiol; 2013 Jun 01; 591(11):2897-909. PubMed ID: 23529132
    [Abstract] [Full Text] [Related]

  • 12. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
    Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA.
    J Clin Invest; 2014 Feb 01; 124(2):509-14. PubMed ID: 24463448
    [Abstract] [Full Text] [Related]

  • 13. Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.
    Vestergaard ET, Hjelholt AJ, Kuhre RE, Møller N, Larraufie P, Gribble FM, Reimann F, Jessen N, Holst JJ, Jørgensen JOL.
    J Clin Endocrinol Metab; 2019 Jul 01; 104(7):2581-2592. PubMed ID: 30726969
    [Abstract] [Full Text] [Related]

  • 14. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
    Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, DeFronzo RA, Norton L, Abdul-Ghani M.
    Diabetes Care; 2016 Nov 01; 39(11):2036-2041. PubMed ID: 27561923
    [Abstract] [Full Text] [Related]

  • 15. Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study.
    Abdul-Ghani M, Migahid O, Megahed A, Singh R, Fawaz M, DeFronzo RA, Jayyousi A.
    Diabetes Obes Metab; 2019 Mar 01; 21(3):705-709. PubMed ID: 30259621
    [Abstract] [Full Text] [Related]

  • 16. Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects.
    Salgin B, Marcovecchio ML, Humphreys SM, Hill N, Chassin LJ, Lunn DJ, Hovorka R, Dunger DB.
    Am J Physiol Endocrinol Metab; 2009 Mar 01; 296(3):E454-61. PubMed ID: 19106250
    [Abstract] [Full Text] [Related]

  • 17. Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.
    Forst T, Alghdban MK, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L.
    Horm Metab Res; 2018 May 01; 50(5):403-407. PubMed ID: 29727906
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
    Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC.
    Eur J Endocrinol; 2003 Dec 01; 149(6):511-9. PubMed ID: 14640991
    [Abstract] [Full Text] [Related]

  • 19. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E, Hansen L, Johnsson E, Iqbal N, Carlsson B, Chen H, Hirshberg B.
    Endocr Pract; 2017 Mar 01; 23(3):258-265. PubMed ID: 27849380
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM, Kelly W, Gries FA, Hubinger A, Whately-Smith C, Alberti KG.
    Metabolism; 1998 Mar 01; 47(3):250-6. PubMed ID: 9500558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.